Tackling Burnout in Your Practice

Thriving in Healthcare

Burnout is a significant problem facing the healthcare industry, and it’s a concern practices and healthcare organizations cannot afford to ignore. Provider and staff burnout affects safety, quality of care, the patient experience and financial performance. So how can you help your employees—and yourself—maintain the passion, focus and energy required to deliver optimal care?

Resilience experts Gary R. Simonds, MD, MHCDS, and Wayne M. Sotile, PhD, authors of the new book Thriving in Healthcare: A Positive Approach to Reclaim Balance and Avoid Burnout in Your Busy Life

Obagi to Host ASDS Panel Discussion on Diversity and Inclusion

Obagi To Host Panel on Diversity in Aesthetics

Skincare company Obagi and actor, producer and activist Priyanka Chopra Jonas will lead a panel of top dermatologists in a discussion about the importance of diversity and inclusion in medical aesthetics on October 24 in Chicago during the annual meeting of the American Society for Dermatologic Surgery (ASDS). The panel, entitled “Be the Change: Discussing Diversity, Inclusion & Medical Aesthetics,” will include Jeanine Downie, MD, FAA, Annie Chiu, MD, Jose Raul Montes, MD, MD, FACS, FACCS and Suzan Obagi, MD.

Moran Takes the Helm of AAFPRS

AAFPRS President

Mary Lynn Moran, MD, FACS has been elected president of the American Academy of Facial Plastic and Reconstructive Surgery(AAFPRS) and will serve a one-year term. Dr. Moran is the first female surgeon to serve as president of the AAFPRS. Based in Franklin, Tennessee, she focuses on cosmetic and reconstructive surgery of the face and neck, as well as advanced nonsurgical techniques. Dr. Moran has extensive experience in the surgical rejuvenation of the aging face, rhinoplasty, revision rhinoplasty and is a nationally renowned expert in neurotoxins and filler injections.

Phase 2 Results for Investigational Ready-To-Use Botulinum Toxin

Galderma Investigating Liquid, Ready to Use Botulinum Toxin

Galderma recently announced the Phase 2 clinical trial results for its novel ready-to-use investigational botulinum toxin, QM1114. The multicenter, randomized, double-blind, placebo-controlled study successfully demonstrated the safety and efficacy of QM1114, a liquid formulation of botulinum toxin type A, for the treatment of glabellar lines in more than 350 patients. According to a release from the company, the Phase 3 clinical trial program, which will include approximately 1,500 subjects, will begin soon to support regulatory submissions globally.

RAP Speeds Laser Tattoo Removal

Lasers in Surgery and Medicine

A recent study published in Lasers in Surgery and Medicine (October 2019) showed that when Rapid Acoustic Pulse (RAP) technology is applied for one minute after each Q-switched (QS) laser tattoo removal pass, it clears the whitening caused by the previous QS laser pass. This allows practitioners to perform additional effective laser passes immediately.

HHS Proposes Stark Law and Anti-Kickback Statute Reforms

On October 9, the Department of Health and Human Services (HHS) announced proposed changes to modernize and clarify the regulations that interpret the Physician Self-Referral Law (the “Stark Law”) and the Federal Anti-Kickback Statute. The proposed rules provide greater certainty for healthcare providers participating in value-based arrangements and providing coordinated care for patients. The proposals would ease the compliance burden for healthcare providers across the industry, while maintaining strong safeguards to protect patients and programs from fraud and abuse.

BTX Ability To Contract Dermal Fibroblasts Varies by Formulation and Dilution

How Botulinum Toxins Lift Skin

Intradermal botulinum toxin injections can cause dermal fibroblast contraction, providing a lifting effect for facial rejuvenation, but this effect varies based on brand and dilution. In an effort to determine how—and whether—intradermal botulinum toxins create visible lifting in the midface, researchers Rungsima Wanitphakdeedecha MD, MA, MSc, et al, treated normal human dermal fibroblasts with onabotulinumtoxin (ONA), abobotulinumtoxin (ABO), prabotulinumtoxinA (PRABO), incobotulinumtoxinA (INCO), and letibotulinumtoxin A (LETI) in varying dilutions.

Online Business Platform for Aesthetic Practices Now Live

Practice Management e-Platform

The Aesthetic Business Institute (ABI) has launched an online educational platform for aesthetic industry members. The platform provides resources for physicians, practice managers and the growing number of entrepreneurial business owners within the aesthetic industry. As an e-learning consortium and membership-based platform, ABI is designed to provide its members with business intelligence tools, industry research, turnkey operational and financial guidance, and a unique practice management certification curriculum to help medspa and practice owners develop and/or grow their businesses.